BMJ says Avastin is just as effective at tackling wet age-related macular degeneration as the current treatment, Lucentis . 
  Drug company Novartis has allegedly tried to ‘do everything’ it can to stop trials of the cancer drug . 
  It is estimated widespread use of the drug would save the NHS around £102million a year . 
 